Evenity (Romosozumab) Adolescent (12-17) Developmental Impact

What Is Romosozumab and Why Does It Matter for Adolescents?

Romosozumab is a monoclonal antibody that binds and inhibits sclerostin, a protein produced by osteocytes that normally suppresses bone formation. Blocking sclerostin simultaneously increases bone formation markers and decreases bone resorption markers, a dual effect not seen with bisphosphonates or teriparatide alone. FDA prescribing information confirms approval for postmenopausal women with high fracture risk.

Why Adolescents Are a Distinct Population

Adolescence is the single most consequential period for skeletal development. Roughly 40% of peak bone mass is accumulated between ages 11 and 17, with the greatest accrual during the pubertal growth spurt. Rizzoli et al. (2010), published in Osteoporosis International, documented that peak bone mass achieved by early adulthood is one of the strongest determinants of osteoporotic fracture risk decades later.

Growth plates (physes) remain open throughout adolescence. Any pharmacological intervention that alters the Wnt signaling pathway, which sclerostin inhibition directly modifies, could theoretically alter chondrocyte proliferation and longitudinal bone growth. This concern has no definitive clinical answer yet.

The Sclerostin-Puberty Connection

Sclerostin levels are not static during puberty. A 2013 study in the Journal of Clinical Endocrinology and Metabolism showed circulating sclerostin concentrations vary significantly by pubertal Tanner stage and differ between sexes, with boys showing higher absolute levels than girls at matched stages. Estrogen independently suppresses sclerostin, which may partly explain the accelerated bone accrual in girls during early puberty. This sex-dependent baseline complicates any attempt to extrapolate adult dosing to adolescents.

FDA Approval Status and Regulatory Context

Romosozumab carries no FDA approval for patients under 18. The FDA granted approval in April 2019 exclusively for postmenopausal women at high risk of fracture, defined as a history of osteoporotic fracture or multiple risk factors for fracture, or patients who have failed or are intolerant to other therapies. FDA approval announcement.

Black-Box Cardiovascular Warning

The prescribing label carries a black-box warning stating that romosozumab "may increase the risk of myocardial infarction (MI), stroke, and cardiovascular death." In the ARCH trial (N=4,093), romosozumab followed by alendronate showed a higher rate of serious cardiovascular events compared to alendronate alone (2.5% vs. 1.9%, P<0.05) over 24 months. Saag et al., NEJM 2017 reported this finding. Adolescents with underlying connective tissue disorders, congenital heart disease, or other cardiac risk factors would face an amplified version of this concern.

Pediatric Regulatory Pathway

Under the Pediatric Research Equity Act (PREA), sponsors may be required to study drugs in pediatric populations when the adult indication could reasonably affect children. As of this writing, Amgen has not received a formal pediatric labeling approval. A PREA waiver or deferral may apply given that postmenopausal osteoporosis has no pediatric analog. FDA pediatric study requirements outline this framework.

Bone Formation Mechanisms During Adolescent Skeletal Development

Understanding how romosozumab might interact with adolescent bone biology requires a brief look at normal skeletal development. Bone modeling in adolescents is predominantly Wnt-pathway driven. Wnt signaling promotes osteoblast differentiation and inhibits osteoclast activity through the RANK-L/OPG axis. Baron and Kneissel (2013), Nature Medicine provided a comprehensive mechanistic review.

Wnt Signaling and the Adolescent Physis

The growth plate's chondrocytes also express Wnt pathway components. Pre-clinical studies in mice showed that sclerostin knockout (functional equivalent of romosozumab's action) produced not only higher trabecular bone density but also changes in cortical geometry and, in some models, altered physeal cartilage thickness. Collette et al. (2012), Bone described these physeal changes in detail. Whether a 12-month course of romosozumab at clinical doses replicates this in human adolescents remains unknown.

Cortical Versus Trabecular Effects

In adult women, romosozumab preferentially increases trabecular bone volume early, with cortical effects lagging by several months. Adolescents normally accrue bone in a different ratio: the pubertal spurt is associated with more periosteal apposition and cortical thickening than is typically seen in postmenopausal treatment trials. A drug that predominantly boosts trabecular volume may not mirror the naturally occurring periosteal gains of puberty, leaving a mismatch in bone geometry that has not been studied prospectively in adolescents. Seeman (2008), Journal of Musculoskeletal and Neuronal Interactions outlined these adolescent bone geometry changes.

Sex Hormone Interactions

Estrogen and testosterone both regulate sclerostin expression and osteoblast activity. During puberty, rapidly rising estrogen suppresses sclerostin independently of any pharmacological agent. Adding romosozumab on top of endogenous estrogen-mediated sclerostin suppression might produce additive effects on bone formation markers that exceed anything studied in adults. Mödder et al. (2011), JCEM documented estrogen's direct role in suppressing sclerostin in premenopausal women, a finding relevant to adolescent girls in mid-to-late puberty.

Clinical Trials Involving Pediatric Patients

No completed Phase 3 trial has evaluated romosozumab specifically in adolescents aged 12 to 17. However, one ongoing study warrants close attention.

NCT03863171: Romosozumab in Osteogenesis Imperfecta

ClinicalTrials.gov identifier NCT03863171 describes a Phase 2 study evaluating romosozumab in children and young adults aged 2 to 17 with osteogenesis imperfecta (OI). OI involves defective type I collagen and leads to fragile bones, frequent fractures, and growth impairment. The study uses BMD Z-score change and fracture rate as primary endpoints. Results from this trial will be the first controlled pediatric bone density data for romosozumab in open-physis patients and are expected to inform whether a broader adolescent indication warrants pursuit.

Evidence From Adjacent Pediatric Bone Conditions

For conditions causing severe childhood osteoporosis, such as glucocorticoid-induced bone loss, spinal muscular atrophy, or cerebral palsy with immobilization, bisphosphonates remain the pediatric standard of care. Ward et al., Pediatrics 2007 reviewed intravenous pamidronate as the reference agent in these settings. Romosozumab has not been compared head-to-head against pediatric bisphosphonate regimens in any published trial.

Compassionate Use and Case Reports

A small number of compassionate-use case reports have described romosozumab in adolescents with severe OI who failed bisphosphonate therapy. These reports, largely from European centers, show BMD Z-score improvements of 15 to 25% at the lumbar spine over 12 months without reported growth deceleration. These are not controlled data, and publication bias toward positive outcomes limits interpretation. Tournis and Dede (2018), Metabolism contextualized anabolic therapy in pediatric bone disease, noting the overall paucity of randomized data.

Growth Plate Safety: What the Science Actually Shows

This section addresses the most clinically sensitive concern for adolescent use.

Wnt Pathway and Physeal Chondrocytes

Chondrocytes in the growth plate proliferative zone express LRP5 and LRP6, the co-receptors that sclerostin normally inhibits. Removing sclerostin's brake on these receptors could accelerate chondrocyte maturation, alter the rate of physeal fusion, or change the geometry of the metaphyseal-diaphyseal junction. Kugimiya et al. (2007), PLOS ONE showed that beta-catenin activation in chondrocytes promotes premature differentiation, which raises a theoretical question about whether sustained sclerostin inhibition could accelerate physeal closure.

Animal Data on Growth Plate

In cynomolgus monkeys treated with romosozumab at doses 3 to 10 times the human equivalent, bone formation increased markedly without macroscopic physeal abnormalities at 12 months per the FDA pharmacology review embedded in the 2019 NDA. However, monkey physes close on a different timeline than human adolescent physes, and the study did not measure final tibial length or long-bone geometry against age-matched controls with statistical power adequate for detecting a 2 to 3% change in growth velocity. FDA pharmacology review for romosozumab (2019) contains this preclinical dataset.

The Absence of Evidence Problem

No published human data confirm physeal fusion acceleration from romosozumab in ages 12 to 17. The absence of evidence is not evidence of safety. Clinicians considering off-label use should obtain baseline and follow-up bone age radiographs (non-dominant hand and wrist) at 6-month intervals, compare skeletal age advancement to chronological age, and document growth velocity in centimeters per 6 months against established Tanner-stage norms. Greulich and Pyle atlas methodology remains the standard for bone age assessment in this context.

Hormonal Axis Considerations

Hypothalamic-Pituitary-Gonadal Axis

Romosozumab does not directly target the hypothalamic-pituitary-gonadal (HPG) axis. Animal reproductive toxicology studies showed no adverse effects on fertility at standard doses per FDA labeling. Nevertheless, the indirect relationship between bone metabolism and gonadal hormone levels is real. Low bone density in adolescents correlates with functional hypothalamic amenorrhea in girls, and any anabolic bone agent that shifts bone turnover markers substantially may alter the feedback environment for gonadotropin-releasing hormone pulses. Gordon et al., JCEM 2017 reviewed the bone-energy-reproduction axis in adolescent athletes, providing mechanistic context.

Growth Hormone and IGF-1 Interactions

Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) are the primary drivers of longitudinal growth in adolescents. Both GH and IGF-1 increase osteoblast activity through pathways that overlap with Wnt signaling. Combining romosozumab's sclerostin-blocking effects with endogenous GH-IGF-1 surges during peak puberty could produce bone formation responses that exceed anything observed in adults. Whether this produces beneficial outcomes (higher peak bone mass) or pathological ones (cortical stress reactions, altered geometry) is genuinely unknown. Giustina et al. (2008), Endocrine Reviews outlined GH's skeletal effects comprehensively.

Vitamin D and Calcium Requirements

Adolescents have higher daily calcium requirements (1,300 mg) than adults (1,000 mg) per NIH Office of Dietary Supplements calcium fact sheet. Romosozumab's anabolic effect on bone formation increases calcium deposition in new bone matrix, creating a transient demand for additional dietary or supplemental calcium. Hypocalcemia is a documented side effect of romosozumab per FDA labeling. Adolescents with low dietary calcium intake, common in girls who avoid dairy, could develop symptomatic hypocalcemia more readily than adequately supplemented adults. Pre-treatment calcium and 25-hydroxyvitamin D assessment is mandatory before adult use and would be even more critical in adolescents.

Adult Efficacy Data: The Benchmark for Comparison

Because no adolescent Phase 3 efficacy data exist, adult trial outcomes define what benefit is theoretically plausible.

FRAME Trial (N=7,180)

The Fracture Study in Postmenopausal Women with Osteoporosis (FRAME) randomized 7,180 postmenopausal women to romosozumab 210 mg monthly or placebo for 12 months, then all crossed to denosumab. Cosman et al., NEJM 2016 reported a 13.3% gain in lumbar spine BMD and 7.1% gain in total hip BMD at 12 months with romosozumab versus placebo. Vertebral fracture risk fell by 73% at 12 months. These numbers represent a ceiling of achievable benefit in an adult osteoporotic skeleton; an adolescent skeleton with active bone formation machinery might respond differently, possibly more robustly, but the clinical relevance of BMD changes during puberty differs from that in a postmenopausal woman.

ARCH Trial (N=4,093)

Saag et al., NEJM 2017 compared romosozumab followed by alendronate to alendronate alone over 24 months in 4,093 postmenopausal women with prior vertebral fracture. The romosozumab sequence produced a 6.2% greater gain in lumbar spine BMD and a 48% reduction in new vertebral fractures compared to alendronate alone. These data anchor the drug's efficacy argument, but translating fracture reduction data from postmenopausal women to adolescents with entirely different fracture risk profiles is not straightforward.

Sequential Therapy Considerations

Adult protocols pair romosozumab with an antiresorptive (bisphosphonate or denosumab) after the 12-month anabolic course to preserve BMD gains. In adolescents, the same antiresorptive question arises. Stopping romosozumab without follow-on therapy results in BMD loss within 12 months per adult data. Committing a 14-year-old to years of subsequent antiresorptive therapy for a non-emergency indication raises concerns that adult protocols simply do not address.

Risk-Benefit Framework for Adolescent Prescribers

The following framework is intended to guide clinicians who encounter an adolescent for whom romosozumab is being considered. It is not a substitute for individualized specialist consultation.

Step 1. Confirm severity. Romosozumab should only enter the differential for adolescents with a BMD Z-score of <-2.0 at the lumbar spine or total body less head, confirmed on DXA using pediatric reference data, combined with a history of two or more low-trauma fractures or one vertebral compression fracture.

Step 2. Exhaust standard options. Intravenous pamidronate, oral alendronate (where evidence exists), and calcium plus vitamin D optimization should be documented as tried or contraindicated before considering romosozumab. Bachrach and Ward (2009), JCEM outlined the pediatric osteoporosis treatment ladder.

Step 3. Cardiology clearance. Given the black-box cardiovascular warning, adolescents with any structural cardiac disease, arrhythmia, or uncontrolled hypertension should have formal cardiology clearance before starting romosozumab.

Step 4. Baseline bone age. Obtain a non-dominant hand and wrist radiograph interpreted using the Greulich-Pyle atlas before the first dose. Repeat at 6 and 12 months. Document skeletal age versus chronological age.

Step 5. Informed consent with documented uncertainty. Families and patients must understand that no Phase 3 adolescent safety data exist. The consent conversation should be documented and, where possible, conducted through a pediatric ethics consultation.

Step 6. Post-treatment plan. Define before starting what antiresorptive agent will be used after the 12-month romosozumab course ends, at what dose, and for how long, to prevent the BMD rebound seen in adult trials without sequential therapy.

Monitoring Parameters During Adolescent Use

If romosozumab is used in an adolescent under specialist guidance, the following minimum monitoring applies.

Laboratory Monitoring

Serum calcium, phosphate, albumin, 25-hydroxyvitamin D, and creatinine should be checked at baseline, month 1, month 3, month 6, and month 12. NIH calcium and vitamin D fact sheets specify laboratory thresholds for deficiency. Bone turnover markers (serum procollagen type I N-terminal propeptide, P1NP; and C-terminal telopeptide, CTX) should be checked at baseline and month 3 to confirm pharmacodynamic response.

Growth Monitoring

Height and weight should be measured at every clinical visit using a calibrated stadiometer. Growth velocity in cm per 6 months should be compared to Tanner-stage-appropriate norms. Tanner and Davies (1985), Journal of Pediatrics established the reference velocity curves still used in clinical practice. A drop of more than 1 cm per 6 months below the expected velocity for Tanner stage warrants drug interruption and specialist reassessment.

DXA and Imaging

DXA at baseline and at 12 months using the same machine and pediatric reference software. Use areal BMD Z-score, not T-score, in anyone under 20. Vertebral fracture assessment (VFA) or lateral spine radiographs at baseline to capture silent compression fractures. International Society for Clinical Densitometry (ISCD) 2019 pediatric position statement mandates Z-score reporting for pediatric DXA.

Cardiovascular Monitoring

Blood pressure at every visit. Resting ECG at baseline. Any chest pain, syncope, or palpitation warrants immediate cardiology referral and drug hold pending evaluation.